WATERTOWN, Mass., November 5, 2024 – Orna Therapeutics, a biotechnology company dedicated to designing and delivering a new class of circular RNA medicines and unprecedented lipid nanoparticle (LNP) delivery solutions for oncology and autoimmune diseases, today announced an upcoming poster presentation at the 66th American Society of Hematology (ASH) Annual Meeting in San Diego from December 7-10, 2024. The presentation will outline data supporting the exploration of its in vivo CAR therapy appr

- Leading efficient care management for the elderly with unimpeded smartcare SEOUL, South Korea, Nov. 23, 2024 /PRNewswire/ -- JCF Technology is a startup that independently developed 'MecKare', a radar sensor that measures biological signals in a non-contact manner, and provides a platform service that automatically connects users and guardians in two-way emergency situations through an artificial intelligence analysis system. Since its establishment in 2016, it has developed a highly accurate

FRIDAY, Nov. 22, 2024 -- Opioid use disorder (OUD) treatment continued to increase in intervention clinics in the third year of implementation of the Massachusetts office-based addiction treatment (OBAT) model of nurse care management for OUD, according to a study published online Nov. 22 in JAMA Network Open . Gwen T. Lapham, Ph.D., M.P.H., from the Kaiser Permanente Washington Health Research Institute in Seattle, and colleagues compared OUD medication treatment in intervention and usual care

FRIDAY, Nov. 22, 2024 -- Menopausal hormone therapy (mHT) is not associated with long-term cognitive effects versus placebo, according to a study published online Nov. 21 in PLOS Medicine . Carey E. Gleason, Ph.D., from the University of Wisconsin in Madison, and colleagues examined the long-term effects of mHT initiated in early menopause in participants enrolled in the Kronos Early Estrogen Prevention Study (KEEPS)-Cog trial and its parent study (KEEPS), in which women were randomly assigned

SATURDAY, Nov. 23, 2024 -- So, you have managed to shed 30 pounds with the help of one of the new blockbuster GLP-1 drugs, but as the holidays near you worry about how to handle gatherings where decadent food will be served in abundance. Luckily, one expert from Baylor College of Medicine has tips on how to enjoy holiday fare while on these medications, without overdoing it. GLP-1 medications, which include Ozempic , Wegovy , Mounjaro and Zepbound , curb appetite and slow the digestion of food,

FRIDAY, Nov. 22, 2024 -- Diagnosis of postpartum depression increased significantly across all racial and ethnic groups and body mass index categories over the past decade, according to a study published online Nov. 20 in JAMA Network Open . Nehaa Khadka, Ph.D., from Kaiser Permanente Southern California in Pasadena, and colleagues evaluated recent trends in postpartum depression to see how these trends are associated with race, ethnicity, and prepregnancy body mass index. The analysis included

FRIDAY, Nov. 22, 2024 -- The U.S. Food and Drug Administration has expanded the age indication for Nerivio, making it the first and only remote electrical neuromodulation (REN) wearable for migraine treatment for children aged 8 years and older. The approval marks the first FDA-cleared, nondrug therapy for acute treatment of migraine in children and the only prescribed preventive treatment of migraine for children in this age group. The approval is based on real-world data showing the safety an

President-elect Donald Trump has named Johns Hopkins surgical oncologist Marty Makary as his nominee for FDA commissioner, confirming recent speculation that he was the frontrunner for the role.If confirmed by the US Senate, Makary's job would be to oversee the agency's $7-billion budget and report to the health secretary. Last week, Trump chose Robert F. Kennedy Jr., known for his critical stance on vaccines and federal health bodies, as his pick for Secretary of Health and Human Services (HHS)

The FDA on Friday approved BridgeBio Pharma's Attruby (acoramidis) to reduce cardiovascular death and cardiovascular-related hospitalisation in patients with transthyretin amyloid cardiomyopathy (ATTR-CM), setting up a showdown with Pfizer's tafamidis, which has the same mechanism of action, but a more limited label. The clearance for Attruby, an oral TTR stabiliser, specifies that the drug provides near-complete stabilisation of TTR, which is not present in the tafamidis indication. The list pr

Elon Musk's brain-computer interface implant startup Neuralink has received approval from Health Canada to perform a clinical trial on its N1 brain implant and R1 robot, which is used to place the implant into the brain. The ‘Canadian Precise Robotically Implanted Brain-Computer Interface’ (CAN-PRIME) study will be performed by the University Health Network (UHN) hospital at its Toronto Western Hospital. CAN-PRIME will assess the safety of the company's N1 implant, designed to allow individual